Automated Detection and Diagnosis of Pathological DRGs in PHN Patients Using Deep Learning and Magnetic Resonance

March 5, 2024 updated by: Xianwei Zhang,MD, Huazhong University of Science and Technology
Here, this study aimed to develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning. This study retrospectively analyzed the DRG images of all patients with postherpetic neuralgia who underwent magnetic resonance neuroimaging examinations in our radiology department from January 2021 to February 2022. After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model. Model performance was evaluated using metrics such as precision, recall, Average Precision, mean average precision and F1 score.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Our previous research has confirmed differences in macroscopic and microscopic aspects between the imaging of lesioned dorsal root ganglia (DRG) in patients with postherpetic neuralgia (PHN) and healthy controls. Additionally, our study revealed that while lesioned skin localization is a classic method in clinical practice, there is still a certain rate of discrepancy with the lesioned DRG observed in magnetic resonance imaging (MRI). This suggests the significant value of MRI in diagnosing lesioned DRG in PHN patients. For patients with zoster sine herpete neuralgia, it is even more crucial to identify the lesioned DRG through MRI. However, due to the small size and varied morphology of DRG lesions, diagnosing lesioned DRG through MRI requires specialized knowledge in neuroanatomy and imaging, posing a challenge to clinical practitioners. Identifying lesioned DRG rapidly and accurately is crucial for interventional therapy, as it serves as an essential treatment target for neuropathic pain.

The YOLO (You Only Look Once) series of algorithms are currently widely used single-stage real-time object detection algorithms, including YOLOv1-YOLOv8. Due to their extremely high detection speed, they enable real-time object detection. YOLOv5 and YOLOv8 are now extensively employed in various applications such as autonomous driving, video surveillance, and object tracking. Moreover, the YOLO series is increasingly being applied in the medical field, including tumor and joint capsule lesion detection, demonstrating good accuracy, recall rates, and detection efficiency. This study aims to utilize the YOLOv8 algorithm to develop a fast and accurate object detection model, simultaneously evaluating its performance. It seeks to validate the feasibility and effectiveness of detecting lesioned dorsal root ganglia (DRG) in real-time postherpetic neuralgia using this model, providing a basis for early diagnosis for clinical practitioners and enabling rapid and precise localization of lesioned DRG.

Study Type

Observational

Enrollment (Actual)

41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Wuhan, China
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with postherpetic neuralgia due who underwent magnetic resonance neuroimaging examinations in the Radiology Department at our hospital from January 2021 to February 2022.

Description

Inclusion Criteria:

  • Patients aged 18 years or older;
  • Patients with herpes zoster who continue to experience pain for over one month after the crust forms over the skin lesions;
  • Clear MRI images showing evident dorsal root ganglia (DRG) lesions.

Exclusion Criteria:

  • Patients with severe systemic, metabolic, or neurological diseases that can lead to polyneuropathy, such as multiple myeloma, diabetes, or thyroid diseases;
  • Patients with a history of psychiatric disorders, other chronic pain conditions, or substance abuse;
  • Patients with a history of thoracic or back surgeries and a history of pain;
  • Presence of artifacts in the imaging or unclear image display;
  • Target images obscured by other tissues.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning
Time Frame: 202310-202402
the You Only Look Once (YOLO) version 8 was selected as the target algorithm model
202310-202402

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

January 31, 2024

Study Completion (Actual)

January 31, 2024

Study Registration Dates

First Submitted

February 16, 2024

First Submitted That Met QC Criteria

February 16, 2024

First Posted (Actual)

February 23, 2024

Study Record Updates

Last Update Posted (Estimated)

March 6, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Deep Learning

3
Subscribe